Lubiprostone Successfully Completes Phase 3 Efficacy Trial In Japanese Patients Suffering From Chronic Idiopathic Constipation
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) and Abbott (NYSE:ABT) today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data…
This entry was posted on Wednesday, June 9th, 2010 at 11:00 pm and is filed under Irritable Bowel Syndrome. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.